Deprenyl treatment restores serum insulin-like growth factor-I (IGF-I) levels in aged rats to young rat level

De la Cruz CP, Revilla E, Rodriguez-Gomez JA,
Vizuete ML, Cano J, Machado A
Departamento de Bioquimica,
Bromatologia y Toxicologia,
Facultad de Farmacia,
Universidad de Sevilla, Spain.
Eur J Pharmacol 1997 May 30; 327(2-3):215-20

ABSTRACT

We studied the effects of treatment with (-)-deprenyl, a monoamine oxidase B inhibitor, on plasma levels of insulin-like growth factor-I (IGF-I) (as indicator of growth hormone (GH) secretion), levels of monoamines and their metabolites, and the activity and content of tyrosine hydroxylase - the rate-limiting enzyme in the biosynthesis of catecholamines - in the hypothalamus and hypophysis of old male rats.  Male Wistar rats (22 months old) were treated with 2 mg deprenyl/kg body weight s.c. three times a week for 2 months.  At the end of the treatment period, blood was collected for measurement of plasma IGF-I levels by radioimmunoassay (RIA).  The concentrations of dopamine, serotonin (5-HT) and their main metabolites were determined by high performance liquid chromatography (HPLC) with electrochemical detection, and the tyrosine hydroxylase content in hypothalamus and hypophysis was determined by enzyme-linked immunoabsorbent assay (ELISA). (-)-Deprenyl treatment produced a pronounced increase in dopamine and 5-HT in both the hypothalamus and hypophysis (P < 0.01).  The main dopaminergic metabolite, 3,4-dihydroxyphenylacetic acid (DOPAC), decreased in hypothalamus but not in hypophysis, and treatment had no effect on the concentration of 5-hydroxyindole-3-acetic acid (5-HIAA).  The tyrosine hydroxylase activity and tyrosine hydroxylase content increased in hypothalamus and hypophysis (P < 0.05). In the hypophysis the increase in tyrosine hydroxylase activity was consistent with the increase in tyrosine hydroxylase amount. Moreover, (-)-deprenyl treatment restored the IGF-I plasma levels in old rats to a concentration similar to those found in young animals. Postulated anti-aging effects of (-)-deprenyl could hence be due to restoration of hypothalamic hormones such as GH.
  • Deprenyl   is an effective antidepressant
  • Deprenyl   in treatment-resistant older depressive patients
  • Deprenyl   + phenylalanine was beneficial in 90% of depression patients
  • Deprenyl   antidepressant effects are by means other than MAO-B inhibition

     Deprenyl   treated rats were much more sexually active
    Deprenyl       enhances sexual performance and longevity in rats
    Deprenyl   may delay the deterioration of neurons during aging
  • Deprenyl   the history of deprenyl
  • Deprenyl   decreases susceptibility to Parkinson's & Alzheimer's disease
  • Deprenyl   restores IGF-1 to youthful levels
  • Deprenyl   protects the vascular endothelium from beta amyloid plaque
  • Deprenyl   reduces cocaine "high"
  • Deprenyl   prolongs animal lifespan by reducing oxidative damage to the brain
  • Deprenyl   may be useful in the treatment of cocaine dependence
  • Deprenyl   increases the life span in Fischer rats
  • Deprenyl   effects on short term memory in young and aged dogs
  • Deprenyl   maintains sexual acitivity in old rats
  • Deprenyl   and Fluoxetine (Prozac) do not interact in combination
  • Deprenyl   prolongs life in elderly dogs
  • Deprenyl   has a cardiac neuroprotective effect
  • Deprenyl   reduces oxidative stress and increases free radical elimination

  • Deprenyl   responses of forebrain neurons to deprenyl

  • Deprenyl   Parkinson's and Alzheimer's patients need 10 mg of deprenyl daily

  • Deprenyl   inhibits tumor growth in rats with mammary tumors

  • Deprenyl   slows the decline of sexual and learning performances in rats

  • Deprenyl   is ten times stronger than methamphetamine as a catecholaminergic

  • Deprenyl   shows favorable results in Tourette's syndrome and narcolepsy

  • Deprenyl   treated rats lived beyond the known maximum lifespan

  • Deprenyl   protects cells from the DNA damage

  • Deprenyl   may protect neurons from ischemic or oxidative damage

  • Deprenyl   prolongs animal lifespan by reducing oxidative damage to the brain

  • Deprenyl   effects on cocaine-induced euphoria

  • Deprenyl   effects on response to experimental cocaine administration  

  • Deprenyl   Are metabolites of deprenyl useful or harmful?

  • Deprenyl   slows the progression of Parkinson's disease

  • Deprenyl   suppresses excitotoxic damage in Parkinson's disease

  • Deprenyl   effect of deprenyl on arm movement in early Parkinson's

  • Deprenyl   effect on cognitive functions in early Parkinson's 

  • Deprenyl   prolongs the life span of Parkinsonian patients significantly

  • Deprenyl   depression in Parkinson's disease

  • Deprenyl   increases the dopamine content of the nerve terminals in Parkinson's

  • Deprenyl   improves visuo-motor control in early Parkinsonism

  • Deprenyl   management of early Parkinson's disease

  • Deprenyl   delays the onset of disability in Parkinsonian patients

  • Deprenyl   and tocopherol antioxidative therapy of Parkinsonism

  • Deprenyl   slows the death of nigral neurons in Parkinson's disease

  • Deprenyl   + levodopa treated Parkinson's patients live longer

  • Deprenyl   stimulates biosynthesis of cytokines interleukin-1 & 6

  • Deprenyl   effect of MAO-B inhibitors on MPP+ toxicity

  • Deprenyl   modulates the activity of catecholamine-sensitive neurons

  • Deprenyl   improves the performance of patients with Alzheimer's disease

  • Deprenyl   MAO-B inhibitors in the treatment of Alzheimer's disease

  • Deprenyl   in the treatment of Alzheimer's disease

  • Deprenyl   stimulates biosynthesis of cytokines interleukin-1 & 6

  • Deprenyl   and age-related decline of the striatal dopaminergic system

  • Deprenyl   increases dopamine in the striatum of primates

  • Deprenyl   use in treatment-resistant elderly depression patients

  • Deprenyl   protects against neurotoxins

  • Deprenyl   effects during smoking and short-term abstinence